Literature DB >> 14718261

Characterization of an anandamide degradation system in prostate epithelial PC-3 cells: synthesis of new transporter inhibitors as tools for this study.

Lidia Ruiz-Llorente1, Silvia Ortega-Gutiérrez, Alma Viso, María G Sánchez, Ana M Sánchez, Carlos Fernández, José A Ramos, Cecilia Hillard, Miguel A Lasunción, María L López-Rodríguez, Inés Díaz-Laviada.   

Abstract

The response of anandamide is terminated by a carrier-mediated transport followed by degradation catalyzed by the cloned enzyme fatty acid amidohydrolase (FAAH). In this study, we provide biochemical data showing an anandamide uptake process and the expression of FAAH in human prostate. Anandamide was accumulated in PC-3 cells by a saturable and temperature-dependent process. Kinetic studies of anandamide uptake, determined in the presence of cannabinoid and vanilloid antagonists, revealed apparent parameters of KM=4.7+/-0.2 microm and Vmax=3.3+/-0.3 pmol min-1 (10(6) cells)-1. The accumulation of anandamide was moderately inhibited by previously characterized anandamide transporter inhibitors (AM404, UCM707 and VDM11) but was unaffected by inhibitors of other lipid transport systems (phloretin or verapamil) and moderately affected by the FAAH inhibitor methyl arachidonyl fluorophosphonate. The presence of FAAH in human prostate epithelial PC-3 cells was confirmed by analyzing its expression by Western blot and measuring FAAH activity. To further study the structural requirements of the putative carrier, we synthesized a series of structurally different compounds 1-8 and evaluated their capacity as uptake inhibitors. They showed different inhibitory capacity in PC-3 cells, with (9Z,12Z)-N-(fur-3-ylmethyl)octadeca-9,12-dienamide (4, UCM119) being the most efficacious, with maximal inhibition and IC50 values of 49% and 11.3+/-0.5 microM, respectively. In conclusion, PC-3 cells possess a complete inactivation system for anandamide formed by an uptake process and the enzyme FAAH. These results suggest a possible physiological function of anandamide in the prostate, reinforcing the role of endocannabinoid system as a neuroendocrine modulator. British Journal of Pharmacology (2004) 141, 457-467. doi:10.1038/sj.bjp.0705628

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14718261      PMCID: PMC1574211          DOI: 10.1038/sj.bjp.0705628

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  50 in total

1.  Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase.

Authors:  María L López-Rodríguez; Alma Viso; Silvia Ortega-Gutiérrez; Christopher J Fowler; Gunnar Tiger; Eva de Lago; Javier Fernández-Ruiz; José A Ramos
Journal:  J Med Chem       Date:  2003-04-10       Impact factor: 7.446

2.  Anandamide activity and degradation are regulated by early postnatal aging and follicle-stimulating hormone in mouse Sertoli cells.

Authors:  Mauro Maccarrone; Sandra Cecconi; Gianna Rossi; Natalia Battista; Riccardo Pauselli; Alessandro Finazzi-Agrò
Journal:  Endocrinology       Date:  2003-01       Impact factor: 4.736

3.  The cellular uptake of anandamide is coupled to its breakdown by fatty-acid amide hydrolase.

Authors:  D G Deutsch; S T Glaser; J M Howell; J S Kunz; R A Puffenbarger; C J Hillard; N Abumrad
Journal:  J Biol Chem       Date:  2000-12-15       Impact factor: 5.157

4.  Activation of phosphoinositide 3-kinase/PKB pathway by CB(1) and CB(2) cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction.

Authors:  María G Sánchez; Lidia Ruiz-Llorente; Ana M Sánchez; Inés Díaz-Laviada
Journal:  Cell Signal       Date:  2003-09       Impact factor: 4.315

Review 5.  Cannabinoid receptors and their endogenous ligands.

Authors:  Takayuki Sugiura; Keizo Waku
Journal:  J Biochem       Date:  2002-07       Impact factor: 3.387

6.  Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production.

Authors:  Murielle Mimeault; Nicole Pommery; Nicole Wattez; Christian Bailly; Jean-Pierre Hénichart
Journal:  Prostate       Date:  2003-06-15       Impact factor: 4.104

7.  Expression of functionally active cannabinoid receptor CB1 in the human prostate gland.

Authors:  Lidia Ruiz-Llorente; María G Sánchez; María J Carmena; Juan C Prieto; Manuel Sánchez-Chapado; Adriana Izquierdo; Inés Díaz-Laviada
Journal:  Prostate       Date:  2003-02-01       Impact factor: 4.104

8.  Estrogen stimulates arachidonoylethanolamide release from human endothelial cells and platelet activation.

Authors:  Mauro Maccarrone; Monica Bari; Natalia Battista; Alessandro Finazzi-Agrò
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

9.  Evidence against the presence of an anandamide transporter.

Authors:  Sherrye T Glaser; Nada A Abumrad; Folayan Fatade; Martin Kaczocha; Keith M Studholme; Dale G Deutsch
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-24       Impact factor: 11.205

Review 10.  N-Acylethanolamines in human reproductive fluids.

Authors:  Herbert Schuel; Lani J Burkman; Jack Lippes; Kent Crickard; Ellyn Forester; Daniele Piomelli; Andrea Giuffrida
Journal:  Chem Phys Lipids       Date:  2002-12-31       Impact factor: 3.329

View more
  15 in total

1.  Inhibition of the cellular uptake of anandamide by genistein and its analogue daidzein in cells with different levels of fatty acid amide hydrolase-driven uptake.

Authors:  L Thors; J Eriksson; C J Fowler
Journal:  Br J Pharmacol       Date:  2007-08-06       Impact factor: 8.739

Review 2.  The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.

Authors:  Roger G Pertwee
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

Review 3.  Detergent-resistant membrane microdomains in the disposition of the lipid signaling molecule anandamide.

Authors:  Matthew J McFarland; Ekaterina A Terebova; Eric L Barker
Journal:  AAPS J       Date:  2006-03-10       Impact factor: 4.009

Review 4.  The endocannabinoid system and cancer: therapeutic implication.

Authors:  Josée Guindon; Andrea G Hohmann
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

Review 5.  Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).

Authors:  S Ventura; V l Oliver; C W White; J H Xie; J M Haynes; B Exintaris
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

6.  The 'specific' tyrosine kinase inhibitor genistein inhibits the enzymic hydrolysis of anandamide: implications for anandamide uptake.

Authors:  L Thors; K Alajakku; C J Fowler
Journal:  Br J Pharmacol       Date:  2007-02-26       Impact factor: 8.739

7.  Expression and function of fatty acid amide hydrolase in prostate cancer.

Authors:  Michael P Endsley; Rebecca Thill; Iffat Choudhry; Carol L Williams; Andre Kajdacsy-Balla; William B Campbell; Kasem Nithipatikom
Journal:  Int J Cancer       Date:  2008-09-15       Impact factor: 7.396

Review 8.  Cannabinoids and multiple sclerosis.

Authors:  Roger G Pertwee
Journal:  Mol Neurobiol       Date:  2007-06-26       Impact factor: 5.590

9.  Studies of anandamide accumulation inhibitors in cerebellar granule neurons: comparison to inhibition of fatty acid amide hydrolase.

Authors:  Cecilia J Hillard; Leyu Shi; Venugopal Raju Tuniki; John R Falck; William B Campbell
Journal:  J Mol Neurosci       Date:  2007-09       Impact factor: 3.444

10.  Inhibition of fatty acid amide hydrolase by kaempferol and related naturally occurring flavonoids.

Authors:  L Thors; M Belghiti; C J Fowler
Journal:  Br J Pharmacol       Date:  2008-06-16       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.